Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
What's AS going to talk about in addition to what Christina already has?
Seems odd, and no new market information as no RNS.
He can't discuss the placing reasoning.
Maybe he'll talk about the website restructure and the new possibilities for pre|CISION.
We'll find out later, at least the SP can't crash while he's talking.
Our presentation at #AACR24 today - well received with many intriguing conversations.
Grateful and humbled by our lead author Prof @udai_banerji who did not stop speaking for 3.5 hours. Udai - much appreciated
#PeptidesCreateHope
#LetsDoThis
@royalmarsdenNHS @ICR_London
From the man administering it
https://twitter.com/udai_banerji/status/1777778199289581619?t=708IDE8BQkgm4QCFErLyXg&s=19
The most important thing for Avacta is that those attending AACR will understand the results from the phase 1 data. From PhD students to big pharma representatives.
Doesn't matter that the institutions who bought in because it sounded cheap still have no idea what any of this science mumbo jumbo means.
Https://twitter.com/coughlin582/status/1777729742852301193?t=HiEl-ONyRNdDXT_vb-J64A&s=19
Https://twitter.com/avacta/status/1777734845189284265?t=wiD_-tbxW9rSSx--aE8Nkg&s=19
All about the ADC's good job pre|CISION can do it better
https://avacta.com/precision-adc/
Copies of the poster will be available on Avacta’s website following the conference at: https://avacta.com/about/resources/posters/.
Christina Coughlin will provide a video presentation overview examining the data presented in the poster. This will be available on 10th April at https://avacta.com/investors/documents-presentations/.